Disc Shares Slip Amid Report FDA’s Prasad is Skeptical of Bitopertin’s Efficacy

The biologics center director reportedly became personally involved after the team reviewing the rare blood disorder filing asked for an extension to the CNPV-accelerated timeline.

Scroll to Top